Safe
Paykan Safe, Irving, TX US
Patent application number | Description | Published |
---|---|---|
20100319348 | WASTE HEAT RECOVERY SYSTEM - A waste heat recovery system in which hot waste fluids, such as flue gasses, pass through a fluid heat exchanger configured to transfer energy in the form of heat to a heat transfer liquid, preferably molten salt. The energy in the molten salt is used to generate useable power such as electrical energy. The waste gas heat recovery system is especially adapted for use with batch processes, such as steelmaking and copper converting, and allows continuous or substantially continuous power production. | 12-23-2010 |
Stephen Safe, College Station, TX US
Patent application number | Description | Published |
---|---|---|
20130267575 | CANCER TREATMENT TARGETING NON-CODING RNA OVEREXPRESSION - Provided herein are methods directed to modulating the pro-oncogenic effects of noncoding RNAs (ncRNAs) through their interactions with specificity protein transcription factors (SpTFs). In one aspect, the disclosure provides a method of inhibiting growth of a cell, such as a transformed or cancer cell, characterized by overexpression of at least one specificity protein (Sp)-regulated ncRNA and expression of at least one Sp transcription factor (SpTF), the method comprising contacting the cell with an effective amount of an SpTF agent. In some embodiments, the ncRNA is a long noncoding RNA (lncRNA). In some embodiments, the ncRNA is a microRNA (miR). Also provided are methods of treating a cell proliferative disease, predicting the response of a subject to SpTF agent-based treatment, and monitoring the efficacy of a SpTF agent-based treatment in a subject. | 10-10-2013 |
Stephen H. Safe, College Station, TX US
Patent application number | Description | Published |
---|---|---|
20080261911 | Uses of diphenyl/diphenylamine carboxylic acids - The present invention demonstrates that chemical-induced degradation of Sp proteins by a specific sub-class of non-steroidal anti-inflammatory drugs inhibited cancer cell growth, angiogenesis and metastasis of cancer cells. The inhibitory effects of these compounds were demonstrated in vitro and in vivo. Hence, the results discussed herein indicate that these compounds can be used to inhibit cell growth, angiogenesis, and metastasis in cancers such as pancreatic cancer, esophageal cancer, breast cancer, prostate cancer, colon cancer, bladder cancer, and ovarian cancer. | 10-23-2008 |
20090099123 | Antisense microRNA and uses therefor - Provided herein are methods to suppress specificity protein (Sp) activity in a cell associated with a cell proliferative disease. The methods are effective to inhibit a microRNA in the cell using an antisense microRNA oligonucleotide which results in an increase in expression of a specificity protein (Sp) suppressor gene thereby inducing Sp degradation, apoptosis or growth arrest by releasing inhibitors of G2/M (Myt-1) or inhibition. Also provided are methods of treating a cancer using the antisense microRNA oligonucleotide. In addition the present invention provides antisense microRNA-27a oligonucleotides useful in the methods described herein. | 04-16-2009 |
20090203661 | Betulinic acid, derivatives and analogs thereof and uses therefor - Provided herein provided herein are novel analogs and derivatives of betulinic acid. Also provided is a method for inhibiting an activity of one or more specificity protein (Sp) transcription factors cells associated with a neoplastic disease using betulinic acid, betulinic acid analog(s) and/or derivative(s) effective to decrease expression of a microRNA with concomitant increase in Sp suppressor gene expression. The betulinic acid analogs and derivatives also are effective in methods provided herein for inhibiting proliferation of cells associated with a neoplastic disease for treating a cancer or for reducing toxicity of a cancer therapy in a subject via administration of an analog or derivative of betulinic acid and, optionally, another anticancer drug. | 08-13-2009 |
20100099760 | Glycyrrhetinic Acid Derivatives - The present invention relates to novel derivatives of glycyrrhetinic acid, compositions comprising said derivatives and their use in the treatment of conditions or diseases that benefit from an upregulation of PPAR&ggr; and/or a downregulation of the expression or activity of one or more specificity (Sp) proteins, such as cancer, diabetes and Huntington's disease. | 04-22-2010 |
20130210926 | GLYCYRRHETINIC ACID DERIVATIVES - The present invention relates to novel derivatives of glycyrrhetinic acid, compositions comprising said derivatives and their use in the treatment of conditions or diseases that benefits from an upregulation of PPARγ and/or a downregulation of the expression or activity of one or more specificity (Sp) proteins, such as cancer, diabetes and Huntington's disease. | 08-15-2013 |
Stephen S. Safe, College Station, TX US
Patent application number | Description | Published |
---|---|---|
20100227906 | C-substituted Diindolylmethane Compositions and Methods for the Treatment of Multiple Cancers - The present embodiment of the invention is generally directed to compositions comprising suspensions of poorly water soluble compounds recrystallized in nanoparticulate sizes ranging from 0.1 to 5 μm. In addition, the embodiment of the invention is directed to methods for preparation and administration of these compositions to a patient for prevention and treatment of disease states. In particular, the embodiment of the invention is directed to compositions comprising suspensions of poorly water-soluble compounds, such as antimitotics and antibiotics, in nanoparticulates and methods of prevention and treatment of chronic disease states, such as cancer, by intraperitoneal and intravenous administration of such compositions | 09-09-2010 |
20120077859 | C-substituted Diindolylmethane Compositions and Methods for the Treatment of Multiple Cancers - The present embodiment of the invention is generally directed to compositions comprising suspensions of poorly water soluble compounds recrystallized in nanoparticulate sizes ranging from 0.1 to 5 μm. In addition, the embodiment of the invention is directed to methods for preparation and administration of these compositions to a patient for prevention and treatment of disease states. In particular, the embodiment of the invention is directed to compositions comprising suspensions of poorly water-soluble compounds, such as antimitotics and antibiotics, in nanoparticulates and methods of prevention and treatment of chronic disease states, such as cancer, by intraperitoneal and intravenous administration of such compositions. | 03-29-2012 |